DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells

Lynn M. Martin; Brian Marples; Anthony M. Davies; Ann Atzberger; Connla Edwards; Thomas H. Lynch; Donal Hollywood; Laure Marignol

doi:10.1016/j.canlet.2013.01.046

DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells

Lynn M. Martin, Brian Marples, Anthony M. Davies, Ann Atzberger, Connla Edwards, Thomas H. Lynch, Donal Hollywood, Laure Marignol

Research output: Contribution to journal › Article

10 Scopus citations

Abstract

DNA repair and G2-phase cell cycle checkpoint responses are involved in the manifestation of hyper-radiosensitivity (HRS). The low-dose radioresponse of MSH2 isogenic endometrial carcinoma cell lines was examined. Defects in cell cycle checkpoint activation and the DNA damage response in irradiated cells (0.2. Gy) were evaluated. HRS was expressed solely in MSH2+ cells and was associated with efficient activation of the early G2-phase cell cycle checkpoint. Maintenance of the arrest was associated with persistent MRE11, γH2AX, RAD51 foci at 2. h after irradiation. Persistent MRE11 and RAD51 foci were also evident 24. h after 0.2. Gy. MSH2 significantly enhances cell radiosensitivity to low dose IR.

Original language	English (US)
Pages (from-to)	19-25
Number of pages	7
Journal	Cancer letters
Volume	335
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2013.01.046
State	Published - Jul 10 2013
Externally published	Yes

Fingerprint

Keywords

Cell cycle arrest
DNA mismatch repair
Endometrial
G2/M
Hypersensitivity
Ionizing radiation
Low dose
MSH2

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

Martin, L. M., Marples, B., Davies, A. M., Atzberger, A., Edwards, C., Lynch, T. H., Hollywood, D., & Marignol, L. (2013). DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells. Cancer letters, 335(1), 19-25. https://doi.org/10.1016/j.canlet.2013.01.046

DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells. / Martin, Lynn M.; Marples, Brian; Davies, Anthony M.; Atzberger, Ann; Edwards, Connla; Lynch, Thomas H.; Hollywood, Donal; Marignol, Laure.

In: Cancer letters, Vol. 335, No. 1, 10.07.2013, p. 19-25.

Research output: Contribution to journal › Article

@article{3a91fbb81508490ab72eb32beb1375d0,

title = "DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells",

abstract = "DNA repair and G2-phase cell cycle checkpoint responses are involved in the manifestation of hyper-radiosensitivity (HRS). The low-dose radioresponse of MSH2 isogenic endometrial carcinoma cell lines was examined. Defects in cell cycle checkpoint activation and the DNA damage response in irradiated cells (0.2. Gy) were evaluated. HRS was expressed solely in MSH2+ cells and was associated with efficient activation of the early G2-phase cell cycle checkpoint. Maintenance of the arrest was associated with persistent MRE11, γH2AX, RAD51 foci at 2. h after irradiation. Persistent MRE11 and RAD51 foci were also evident 24. h after 0.2. Gy. MSH2 significantly enhances cell radiosensitivity to low dose IR.",

keywords = "Cell cycle arrest, DNA mismatch repair, Endometrial, G2/M, Hypersensitivity, Ionizing radiation, Low dose, MSH2",

author = "Martin, {Lynn M.} and Brian Marples and Davies, {Anthony M.} and Ann Atzberger and Connla Edwards and Lynch, {Thomas H.} and Donal Hollywood and Laure Marignol",

year = "2013",

month = jul

day = "10",

doi = "10.1016/j.canlet.2013.01.046",

language = "English (US)",

volume = "335",

pages = "19--25",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells

AU - Martin, Lynn M.

AU - Marples, Brian

AU - Davies, Anthony M.

AU - Atzberger, Ann

AU - Edwards, Connla

AU - Lynch, Thomas H.

AU - Hollywood, Donal

AU - Marignol, Laure

PY - 2013/7/10

Y1 - 2013/7/10

N2 - DNA repair and G2-phase cell cycle checkpoint responses are involved in the manifestation of hyper-radiosensitivity (HRS). The low-dose radioresponse of MSH2 isogenic endometrial carcinoma cell lines was examined. Defects in cell cycle checkpoint activation and the DNA damage response in irradiated cells (0.2. Gy) were evaluated. HRS was expressed solely in MSH2+ cells and was associated with efficient activation of the early G2-phase cell cycle checkpoint. Maintenance of the arrest was associated with persistent MRE11, γH2AX, RAD51 foci at 2. h after irradiation. Persistent MRE11 and RAD51 foci were also evident 24. h after 0.2. Gy. MSH2 significantly enhances cell radiosensitivity to low dose IR.

AB - DNA repair and G2-phase cell cycle checkpoint responses are involved in the manifestation of hyper-radiosensitivity (HRS). The low-dose radioresponse of MSH2 isogenic endometrial carcinoma cell lines was examined. Defects in cell cycle checkpoint activation and the DNA damage response in irradiated cells (0.2. Gy) were evaluated. HRS was expressed solely in MSH2+ cells and was associated with efficient activation of the early G2-phase cell cycle checkpoint. Maintenance of the arrest was associated with persistent MRE11, γH2AX, RAD51 foci at 2. h after irradiation. Persistent MRE11 and RAD51 foci were also evident 24. h after 0.2. Gy. MSH2 significantly enhances cell radiosensitivity to low dose IR.

KW - Cell cycle arrest

KW - DNA mismatch repair

KW - Endometrial

KW - G2/M

KW - Hypersensitivity

KW - Ionizing radiation

KW - Low dose

KW - MSH2

UR - http://www.scopus.com/inward/record.url?scp=84878427186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878427186&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2013.01.046

DO - 10.1016/j.canlet.2013.01.046

M3 - Article

C2 - 23376256

AN - SCOPUS:84878427186

VL - 335

SP - 19

EP - 25

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -

Access to Document

10.1016/j.canlet.2013.01.046